Drugs / IdB 1016
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00055445 | Nov 2003 → Apr 2006 | chronic hepatitis C virus infection | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00443079 | Mar 2007 → Dec 2009 | fatty liver disease | Heather Patton | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IdB 1016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00055445 ↗ |
| Route | Oral | “oral silybin-phosphatidylcholine phytosome” NCT00055445 ↗ |